Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
